PANDEMIC INFLUENZA (H1N1) 2009

INTRODUCTION

Pandemic Influenza A(H1N1) 2009, currently the most common circulating strain of influenza virus globally, first caused illness in Mexico and the United States in March and April, 2009. It continues to spread globally with more than 340,000 laboratory confirmed cases and over 4100 deaths reported to WHO as of 27 September 2009.

It is thought that pandemic influenza (H1N1) 2009 spreads in the same way that regular seasonal influenza viruses spread, mainly through the coughs and sneezes of people who are sick with the virus, but it may also be spread by touching infected objects and then touching nose or mouth. Pandemic (H1N1) 2009 infection has been reported to cause a wide range of flu-like symptoms, including fever, cough, sore throat, body aches, headache, chills and fatigue. In addition, many people also have reported nausea, vomiting and/or diarrhea.

Past Pandemics

1918 pandemic in humans:- The 1918 flu pandemic in humans was associated with Influenza A (H1N1). An estimated one third of the world’s population (or H≈500 million persons) was infected and had clinically apparent illnesses during the 1918–1919 influenza pandemic. The disease was exceptionally severe. Case-fatality rates were >2.5%, compared to <0.1% in other influenza pandemics. Total deaths were estimated at H≈50 million and were arguably as high as 100 million.

Swine influenza was first proposed to be a disease related to human influenza during the 1918 flu pandemic, when pigs became sick at the same time as humans. Although it is not certain in which direction the virus was transferred, some evidence suggests that, in this case, pigs caught the disease from humans. The first identification of an influenza virus as a cause of disease in pigs occurred about ten years later, in 1930. For the following 60 years, swine influenza strains were almost exclusively H1N1. These strains included genes derived due to reassortment from human, swine and avian viruses. The H1N1 form of swine flu is one of the descendants of the strain that caused the 1918 flu pandemic.

1957: “Asian Flu”:- The pandemic occurred due to Influenza A (H2N2) and caused 1-2 million deaths worldwide.

1968: “Hong Kong Flu”:- This pandemic was associated with Influenza A (H3N2) and 700,000 deaths were reported worldwide.

2004-09 till date: Outbreak of H5N1 was reported in 2003 and has affected poultry in 50 countries and caused human infections in 15 countries with 262 deaths and 442 cases as of 24 September 2009.

Current Pandemic: 2009 outbreak in humans

The H1N1 viral strain implicated in the 2009 flu pandemic among humans was earlier referred to as “swine flu” because initial testing showed many of the genes in the virus were similar to influenza viruses normally occurring in North American swine. But further research has shown that the outbreak is due to a reassortant strain of H1N1 not previously reported in pigs.

In late April, World Health Organization, declared a “Public Health Emergency of International Concern” under the rules of the WHO’s new International Health Regulations when the first cases of the H1N1 virus were reported in the United States. On 11 June 2009 WHO declared pandemic phase 6 in response to the spread of new influenza A (H1N1) virus. Monitoring the evolution of the pandemic virus and sharing information for public health response have been key components of the global response.

EPIDEMIOLOGY

Pre-requisites to start Influenza Pandemics

(i) Emergence of a novel virus to which all are susceptible
(ii) New virus is able to replicate and cause disease in humans
(iii) New virus is transmitted efficiently from human-to-human.
**Novel Influenza A (H1N1) Virus:** The 2009 novel A H1N1 virus appears to be of swine origin and contains a unique combination of gene segments that has not been identified in the past. The molecular analysis of the novel H1N1 virus has re-assorted segments from American swine, Eurasian swine, Avian and Human virus. It has not been previously detected in pigs or humans. The present novel virus has shown sensitivity to oseltamivir, but is resistant to both amantadine and rimantadine.

**About the Virus:** It is an enveloped RNA virus and belongs to the family orthomyxoviridae. The size of the virus is 80-200 nm / .08-.012 micron in diameter. There are three types of influenza A virus, namely A, B & C. The virus contains two surface antigens H (hemaglutinin) and N (neuraminidase).

**Person-to-person transmission -** Influenza virus is present in respiratory secretions of infected persons. As a result, influenza virus can be transmitted through droplets by sneezing.

**Incubation period -** Although the precise incubation period has not been established for pandemic H1N1 influenza A infection, it could range from one to seven days, and most likely from one to four days.

**Global Scenario as on 27.09.2009**

<table>
<thead>
<tr>
<th>Regions</th>
<th>Cases</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO Regional Office for Africa (AFRO)</td>
<td>8352</td>
<td>42</td>
</tr>
<tr>
<td>WHO Regional Office for the Americas (AMRO)</td>
<td>137147</td>
<td>3020</td>
</tr>
<tr>
<td>WHO Regional Office for the Eastern Mediterranean (EMRO)</td>
<td>12008</td>
<td>74</td>
</tr>
<tr>
<td>WHO Regional Office for Europe (EURO)</td>
<td>Over 56000</td>
<td>At least 176</td>
</tr>
<tr>
<td>WHO Regional Office for South-East Asia (SEARO)</td>
<td>33594</td>
<td>413</td>
</tr>
<tr>
<td>WHO Regional Office for the Western Pacific (WPRO)</td>
<td>96197</td>
<td>383</td>
</tr>
<tr>
<td>Total</td>
<td>Over 343298</td>
<td>At Least 4108</td>
</tr>
</tbody>
</table>

**Indian Scenario as on 29.09.2009**

<table>
<thead>
<tr>
<th>Total lab confirmed cases (Cumulative )</th>
<th>Death of lab confirmed cases (Cumulative )</th>
</tr>
</thead>
<tbody>
<tr>
<td>10036</td>
<td>308</td>
</tr>
</tbody>
</table>

- The first case in India was reported on 15th May 2009 from Hyderabad
- First death in India was reported on 6th July 2009 from Pune

**SURVIVAL OF THE INFLUENZA VIRUS**

The Pandemic H1N1 influenza virus can survive on different items for different periods. The virus can survive on hard and nonporous surfaces for 24-48 Hours. On plastic & stainless steel, it is recoverable upto 24 hours and can be transferred to hands up to 24 hours. On cloth, paper and tissue, the virus is recoverable for 8-12 hours and transferable to hands up to 15 minutes. The virus can survive at humidity of 35-40% and a temperature of 28°C (82°F).

**CLINICAL MANIFESTATIONS**

The clinical presentations of the H1N1 influenza A pandemic are fever, cough, sore throat, malaise, and headache; vomiting and diarrhoea.

**Children -** Young children are less likely to have the usual influenza signs and symptoms such as fever and cough. Infants may present with fever and lethargy, and may not have cough or other respiratory symptoms. Symptoms of severe disease in infants and young children may include apnoea, tachypnoea, dyspnoea, cyanosis, dehydration, altered mental status, and extreme irritability.

**High Risk Groups -** These risk groups include:
- Children younger than 5 years old;
- Adults 65 years of age and older;
- Chronic pulmonary condition (including asthma), cardiovascular (except hypertension), renal, hepatic, hematological (including sickle cell disease), neurologic, neuromuscular, or metabolic disorders (including diabetes mellitus);
- Immunosuppression, including that caused by medications or by HIV;
- Pregnant women;
- Residents of nursing homes and other chronic-care facilities;
- Obesity.

**CASE DEFINITION OF PANDEMIC INFLUENZA IN HUMANS**

**A suspected case** of the Pandemic Influenza A H1N1 virus infection is defined as a person with acute febrile respiratory illness (reported or documented fever, and one of the following: cough, sore throat, shortness of breath, difficulty in breathing or chest pains) with onset:
- within 7 days of close contact with a person who is a probable or confirmed case of the new influenza A (H1N1) virus infection, or
- within 7 days of travel to a community internationally where there has been one or more confirmed Pandemic influenza A (H1N1) cases, or
- resides in a community where there are one or more confirmed new influenza cases.

**A Probable case** of Pandemic Influenza A (H1N1) 2009 virus infection is defined as an individual with an influenza test that is positive for influenza A, but is unsubtypable by reagents used to detect seasonal influenza virus infection;

OR

An individual with a clinically compatible illness or who died of an unexplained acute respiratory illness who is considered to be epidemiologically linked to a probable or confirmed case.
A Confirmed case of Pandemic Influenza A (H1N1) virus infection is defined as an individual with laboratory confirmed new influenza A (H1N1) virus infection by one or more of the following:

- real-time RT-PCR,
- viral culture
- four-fold rise in new influenza A(H1N1) virus-specific neutralizing antibodies.

Treatment/ Chemoprophylaxis of Influenza A H1N1

**Table 1. Recommended Treatment Dosage of Oseltamivir**

<table>
<thead>
<tr>
<th>Body Weight (kg)</th>
<th>Body Weight (lbs)</th>
<th>Age (years)</th>
<th>Dose for 5 Days</th>
<th># Bottles of Oral Suspension Needed for the 5 Day Regimen</th>
<th># of Capsules Needed for the 5 Day Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;15</td>
<td>&lt;33</td>
<td>1-2</td>
<td>30 mg twice daily</td>
<td>1</td>
<td>10 capsules (30 mg)</td>
</tr>
<tr>
<td>&gt; 15-23</td>
<td>&gt; 33-51</td>
<td>3-5</td>
<td>45 mg twice daily</td>
<td>2</td>
<td>10 capsules (45 mg)</td>
</tr>
<tr>
<td>&gt; 23-40</td>
<td>&gt; 51-88</td>
<td>6-9</td>
<td>60 mg twice daily</td>
<td>2</td>
<td>20 capsules (30 mg)</td>
</tr>
<tr>
<td>&gt; 40</td>
<td>&gt; 88</td>
<td>10-12</td>
<td>75 mg twice daily</td>
<td>3</td>
<td>10 capsules (75 mg)</td>
</tr>
</tbody>
</table>

**Recommended Prophylaxis Dosage of Oseltamivir**

<table>
<thead>
<tr>
<th>Body Weight (kg)</th>
<th>Body Weight (lbs)</th>
<th>Age (years)</th>
<th>Dose by Age</th>
<th>Recommended Treatment Dose for 5 Days</th>
<th># of Capsules Needed for the 5 Day Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;15</td>
<td>&lt;33</td>
<td>1-2</td>
<td>30 mg once daily</td>
<td>12 mg (1 mL) twice daily</td>
<td>10 capsules (30 mg)</td>
</tr>
<tr>
<td>&gt; 15-23</td>
<td>&gt; 33-51</td>
<td>3-5</td>
<td>45 mg once daily</td>
<td>25 mg (1.6 mL) twice daily</td>
<td>10 capsules (45 mg)</td>
</tr>
<tr>
<td>&gt; 23-40</td>
<td>&gt; 51-88</td>
<td>6-9</td>
<td>60 mg once daily</td>
<td>30 mg (2 mL) twice daily</td>
<td>20 capsules (30 mg)</td>
</tr>
<tr>
<td>&gt; 40</td>
<td>&gt; 88</td>
<td>10-12</td>
<td>75 mg once daily</td>
<td>45 mg (3 mL) twice daily</td>
<td>30 capsules (75 mg)</td>
</tr>
</tbody>
</table>

**OSELTAMIVIR / ZANAMIVIR**

Treatment with oseltamivir or zanamivir is recommended for all people with suspected or confirmed influenza who require hospitalization. Treatment with zanamivir or oseltamivir should be initiated as soon as possible after the onset of symptoms. Benefits from antiviral treatment are maximal when treatment is started within 48 hours of illness onset. The recommended duration of treatment is five days. However, hospitalized patients with severe infection might require longer treatment course.

**CONTAINMENT STRATEGIES OF MOHFW (GOI)**

- Early detection, investigation and containment of cases of influenza A H1N1
- Training and equipping manpower to investigate and contain number of cases
- Strengthening of health care infrastructure
- Stockpiling of antiviral drugs, PPE, N-95 and triple layer mask & Oseltamivir
- Preparation of guidelines and standard operating procedures (SOPs) and IEC material
- Management of cases
- Increasing Awareness
- Lab Network for Influenza A H1N1 Surveillance
  - 22 under Government sector
  - 21 under private sector
- Contact Tracing
- Drug Resistance Monitoring
- Enhanced Surveillance

**BROAD GUIDELINES FOR SCHOOLS AND EDUCATIONAL INSTITUTIONS**

1. Schools are advised to avoid any large gathering of students during the course of the day in the school. This would reduce the possibility of the spread of the infection, if any, to a much larger number of students who would be in close contact with each other in such a gathering.

2. It should be made mandatory by the school authorities that all class teachers should begin their class with active screening of each student in the class so as to detect any student who is having symptoms of flu (mild fever with cough/ sore throat with or without body ache, headache, diarrhea and vomiting). If such student is detected, he/she should be referred immediately to the medical facility of the school. He/ She should be further advised to stay at home for 7 days and observe strict discipline of home isolation. The onus of observance of discipline of isolation henceforth is shifted to the parents and school authorities should accordingly write a letter to the parent. The parents should also be advised to keep other wards at home, in case they are found to have flu like symptoms. There should be constant self-monitoring and if symptoms deteriorate, it should be reported to health authorities immediately.

3. Students, teachers and other employees working in schools/educational institutions are advised to stay at home if they develop flu like symptoms. They should consult the medical doctor and take treatment as advised including home isolation and drugs for treatment of the symptoms.

4. Students, teachers and other employees working in schools/educational institutions are advised to continue to stay at home for at least 7 days if they are advised by the doctor to take Oseltamivir treatment and they should observe home isolation. There should be constant self-monitoring and if symptoms deteriorate, it should be reported to health authorities, immediately.

5. School authorities should not insist on production of medical certificate from such absentees.

6. Students, teachers and other employees working in schools/educational institutions are advised to wash their hands frequently with soap and water.
7. Students, teachers and other employees working in schools/educational institutions are advised to observe strict cough / sneeze etiquette i.e. using tissue while sneezing and coughing. The tissue paper so used should be kept in a separate plastic bag, so that it can be disposed of safely.

8. All the schools / educational institutions should observe regular cleaning of the area with cleaner they ordinarily use so that all the droplets and shredding from any unnoticed mildly infected students / employees are taken care of.

9. Closure of schools has not been recommended by Centre for Disease Control, Atlanta, USA. Its value in prevention of spread of disease within school is outweighed by the possibility of community spread, which is more likely because the children will play and mix with public in various places and at social gathering and there will be nobody to advise them or prevent such incidents. On the other hand, in schools there will be a teacher who will be able to detect their symptoms everyday at the earliest. However, school authorities have to use their own judgement for any type of temporary closure in the event of wide spread H1N1 influenza in school.

10. In case of students staying in hostels, the school authority should monitor the health status of students as well as the other ancillary staff in the hostel on regular basis.

11. In case there are suspected cases in the hostel, the authorised local medical authority should be called for examination of all students and school authority should not close the hostel/ send the students back to their home.

12. School should discourage excursion of the students to the affected countries.

13. However, if students go on tour to the affected countries, they should be thoroughly examined on return by medical doctor before permitting attendance in the class. If there is one suspect case of H1N1 then the whole group should be kept under isolation at home and their health status regularly watched.

14. All the schools should display and circulate “DO’S AND DON’TS” for H1N1 infection and frequently asked questions (FAQ) to the students.

### GUIDELINES FOR SAMPLE COLLECTION AND HANDLING OF HUMAN CLINICAL SAMPLES FOR LABORATORY DIAGNOSIS OF H1N1 INFLUENZA

**Whom to test** — Testing for pandemic H1N1 influenza A should be considered in individuals with an acute febrile respiratory illness (a measured temperature of 100ºF or higher and recent onset of at least one of the following: rhinorrhea, nasal congestion, sore throat, or cough).

**Priority for testing should be given to:**
- Those who require hospitalization and
- Those who are at high risk for severe complications

To establish the diagnosis of pandemic H1N1 influenza A, an upper respiratory sample (nasopharyngeal swab, nasal swab, throat swab, combined oropharyngeal/ nasopharyngeal swab, or nasal aspirate) should be collected. In intubated patients, an endotracheal aspirate should also be obtained.

Specimens should be placed in viral transport media and placed on ice (4ºC) or refrigerated immediately for transportation to the laboratory. Once the samples arrive in the laboratory, they should be stored either in a refrigerator at 4ºC or in a -70ºC freezer. If a -70ºC freezer is not available, they should be kept refrigerated, preferably for ≤1 week.

**When to Collect Respiratory Specimens?**
Sample should be collected as soon as possible after symptoms begin, before antiviral medications are administered. Multiple specimens on multiple days could be collected if you have access to patient.

**General Biosafety Measures**
All biosafety measures should be followed and samples should be taken only after wearing full compliment of PPE. After collection of samples, PPE should be disposed off as waste properly as per guidelines.

### RECOMMENDED TESTS

The recommended test to confirm the diagnosis of pandemic H1N1 influenza A virus is real-time reverse transcriptase (RT-PCR) in designated laboratories. The laboratory has to have BSL2 facility and one needs to follow BSL3 precautions while performing tests.

Virus isolation should be carried out only by those laboratories which have BSL3 facility.

### GUIDELINES FOR SCREENING CENTRES AND ISOLATION FACILITIES IN HOSPITALS

All hospitals identified to screen and admit patients with influenza H1N1 should conform to these guidelines. Identified hospitals would have a separate screening area to screen outdoor patients and an isolation facility to admit those requiring indoor treatment. For clarity, these guidelines are in six parts: (i) Generic Guidelines (ii) Guidelines for pre hospital care (iii) Guidelines for the screening centre (iv) Guidelines for isolation facility and (v) Guidelines for critical care (vi) Mortuary care.

(i) **Generic guidance**
- Standard Precautions to be followed at all patient care areas: hand hygiene, Gloves and use of personal protective equipment (PPE) to avoid direct contact with patient’s blood, body fluids, secretions and non-intact skin, prevention of needle stick/sharp injury and cleaning and disinfection of the environment and equipment.
- Droplet precautions to be followed when caring for patients with influenza A H1N1 (masks, respirators and eye shield) in isolation facilities.
- Airborne and Contact Precautions should complement Standard Precautions while managing case of Pandemic influenza A H1N1 in critical care facilities.
- Hospitals should follow the hospital waste management protocols as per the hospital waste management rules.
- Dead body should be handled using full cover of PPE.

(ii) **Guidelines for Pre Hospital Care**
- All identified hospitals to have advanced life support ambulance.
To create a 10 bed facility, a minimum space of 2000 sq feet area clearly segregated from other patient-care areas is required.

However, if sufficient single rooms are not available, beds could be put with a spatial separation of at least 1 meter (3 feet) from one another.

To create a 10 bed facility, a minimum space of 2000 sq feet area clearly segregated from other patient-care areas is required.

(iii) Guidelines for setting up Screening Centre

Purpose of the Screening Centre is to:

- Attend to patients of influenza like illness in a separate area so as to avoid these patients further infecting other patients in Out Patient Department.
- Facilitate implementing standard and droplet precautions.
- Triage the patients.
- Collect samples.

The screening area should have:

- A waiting area of about 2000 sq feet to accommodate 50-100 patients.
- Preferably stand alone building with separate entry.
- Well ventilated to ensure frequent air changes. If air-conditioned, then independent from central air conditioning. Exhaust air to be filtered through HEPA filter (desirable).
- Patient’s seating to have at least one meter clearance on all sides. Avoid overcrowding of patients.
- Will have cabins for registration, clinical examination chambers, sample collection rooms and drug distribution centre.
- The waiting area should be adequately cleaned and disinfected.
- Source control (e.g. use of tissues, handkerchiefs, piece of cloth or triple layer surgical masks to cover nose and mouth) of the patient in the waiting room when coughing or sneezing, and hand hygiene after contact with respiratory secretions.
- Facility for hand wash. / Wash rooms etc.

(iv) Guidelines for setting up isolation facility/ ward

- Patients should be housed in single rooms, whenever possible.
- However, if sufficient single rooms are not available, beds could be put with a spatial separation of at least 1 meter (3 feet) from one another.
- To create a 10 bed facility, a minimum space of 2000 sq feet area clearly segregated from other patient-care areas is required.
(v) Guidelines for Critical Care facility
- At least one identified hospital may have a 10 bed dedicated intensive care facility at state capital.
- The critical care facility is required to follow all the guidelines as mentioned above for infection control.
- Also more than or equal to 12 air changes and maintain negative pressure of 40 psi.
- Should have dedicated equipments. It should also have additional equipments to ventilate at least 10 patients manually.
- A telephone or other method of communication should be set up in the isolation room/area to enable patients or family members/visitors to communicate with nurses inside the facility.
- Would have an information board outside to update relatives on the clinical status.

(vi) Mortuary care
- Mortuary staff should apply standard precautions i.e. perform proper hand hygiene and use appropriate PPE (use of gown, gloves, facial protection if there is a risk of splashes from patient’s body fluids/secretions onto staff’s body and face).
- Embalming, if required should be conducted according to usual procedures, subject to local regulations/legislation.
- Hygienic preparation of the deceased (e.g. cleaning of body, tidying of hair, etc) also may be done using standard precautions.

GUIDELINES FOR THE USE OF MASKS

Types of mask: Specification for Triple Layer Surgical Mask and N-95 Respirator Mask

<table>
<thead>
<tr>
<th>Item</th>
<th>Specification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Triple Layer Surgical Mask</td>
<td>Tie on Mask of Non-woven, Hypoallergenic 3 ply construction with filter in between offering &gt;99 percent standard with 4 tie strings</td>
</tr>
<tr>
<td>N-95 Respirator Mask</td>
<td>Filter efficiency of 95 % or more against particulate aerosols. The mask should be provided with expiration valve. It should be disposable &amp; to be able to fit for wide range of face sizes. It should accompany with certification from NIOSH or any other internationally accepted certification.</td>
</tr>
</tbody>
</table>

The correct procedure of wearing triple layer surgical mask:
- Unfold the pleats, make sure that they are facing down.
- Place over nose, mouth and chin.
- Fit flexible nose piece over nose bridge.
- Secure with tie strings (upper string to be tied on top of head above the ears –lower string at the back of the neck).
- Ensure there are no gaps on either side of the mask, adjust to fit.
- Do not let the mask hanging from the neck.

- Change the mask after six hours or as soon as they become wet.
- Disposable masks are never to be reused and should be disposed off.
- While removing the mask great care must be taken not to touch the potentially infected outer surface of the mask.
- To remove mask first untie the tie-string below and then the tie string above and handle the mask using the upper strings.

Disposal of used masks: Used mask should be considered as potentially infected medical waste:
- In the hospital setting it should be disposed off in the identified infectious waste disposal bag/container.
- In community settings where medical waste management protocol cannot be practiced, it may be disposed off either by burning or deep burial.
- During home care, patients and contacts using triple layer mask should first disinfect used mask with ordinary bleach solution or sodium hypochlorite solution and/or quaternary ammonium household disinfectant and then dispose off either by burning or deep burial.

MANAGEMENT OF SUSPECTED PATIENTS OF INFLUENZA A H1N1

In order to prevent and contain outbreak of Influenza A H1N1 virus for screening, testing and isolation following guidelines (issued by the Govt. of India) are to be followed:

At first, all individuals seeking consultations for flu like symptoms should be screened at designated healthcare facilities or examined by a doctor and these will be categorized as under:

Category-A:
- Patients with mild fever plus cough / sore throat with or without body ache, headache, diarrhoea and vomiting will be categorised as Category-A. They do not require Oseltamivir and should be treated for the symptoms mentioned above. The patients should be monitored for their progress and reassessed at 24 to 48 hours by the doctor.
- No testing of the patient for H1N1 is required.
- Patients should confine themselves at home and avoid mixing up with public and high risk members in the family.

Category-B:
- In addition to all the signs and symptoms mentioned under Category-A, if the patient has high grade fever and severe sore throat, he/she may require home isolation and Oseltamivir;
- In addition to all the signs and symptoms mentioned under Category-A, individuals having one or more of the following high risk conditions shall be treated with Oseltamivir:
  - Children less than 5 years old;
  - Pregnant women;
  - Persons aged 65 years or older;
  - Patients with lung diseases, heart disease, liver disease, kidney disease, blood disorders, diabetes, neurological disorders, cancer and HIV/AIDS;
• Patients on long term cortisone therapy.
• No tests for H1N1 are required for Category-B (i) and (ii).
• All patients of Category-B (i) and (ii) should confine themselves at home and avoid mixing with public and high risk members in the family.

Category-C:
• In addition to the above signs and symptoms of Category-A and B, if the patient has one or more of the following:
  • Breathlessness, chest pain, drowsiness, fall in blood pressure, sputum mixed with blood, bluish discoloration of nails;
  • Irritability among small children, refusal to accept feed;
  • Worsening of underlying chronic conditions.
• All these patients mentioned above in Category-C require testing, immediate hospitalization and treatment including Oseltamivir.

Home Care treatment for Influenza A H1N1
People with novel H1N1 flu, who are cared for at home, should:
• Check with their health care provider about any special care they might need if they are pregnant or have a health condition such as diabetes, heart disease, asthma, or emphysema.
• Check with their health care provider about whether they should take antiviral medications.
• Keep away from others as much as possible. This is to keep from making others sick. Do not go to work or school while ill.
• Stay home for at least 24 hours after fever subsides, except to seek medical care or for other necessities. (Fever should subside without the use of a fever-reducing medicine).
• Get plenty of rest.
• Drink clear fluids (such as water, broth, sports drinks, electrolyte beverages for infants) to keep from being dehydrated.
• Cover coughs and sneezes. Clean hands with soap and water or an alcohol-based hand rub often, especially after using tissues and after coughing or sneezing into hands.
• Wear a facemask – if available and tolerable – when sharing common spaces with other household members to help prevent spreading the virus to others. This is especially important if other household members are at high risk for complications from influenza.
• Be watchful for emergency warning signs that might indicate need to seek medical attention

INFLUENZA A H1N1 VACCINE
Pandemic vaccines have their greatest impact as a preventive strategy when administered before or near the peak incidence of cases in an outbreak. Regulatory authorities have licensed pandemic vaccines in Australia, China and the United States of America, soon to be followed by Japan and several countries in Europe. The Government of India has taken the initiative to fast-track the indigenous production of the H1N1 vaccine in the country.

The seasonal flu vaccine is not expected to protect against the 2009 H1N1 flu. It has been recommended that certain groups of the population receive the 2009 H1N1 vaccine when it first becomes available. These target groups include pregnant women, people who live with or care for children younger than 6 months of age, healthcare and emergency medical services personnel, persons between the ages of 6 months and 24 years old, and people ages of 25 through 64 years of age who are at higher risk for 2009 H1N1 because of chronic health disorders or compromised immune systems. The U.S. Food and Drug Administration (FDA) has approved the use of one dose of 2009 H1N1 flu vaccine for persons 10 years of age and older and two doses for children 9 years of age and younger.

LIST OF INSTITUTIONS UNDER AI LAB NETWORK

<table>
<thead>
<tr>
<th>Name of Centre</th>
<th>Email/Phone /Fax No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sanjaj Gandhi</td>
<td><a href="mailto:director@sppgi.ac.in">director@sppgi.ac.in</a> +91-522-2668004 to 2668008 Fax: +91-522-2668071 to 2668078 0522-2668100 <a href="mailto:tndhole@gmail.com">tndhole@gmail.com</a> (9415025675) <a href="mailto:ltmishra@indiatimes.com">ltmishra@indiatimes.com</a> (9415792525) <a href="mailto:Swatisevena.mbt@gmail.com">Swatisevena.mbt@gmail.com</a> (9758686990)</td>
</tr>
<tr>
<td>Indira Gandhi Medical College, Shilma</td>
<td><a href="mailto:bvs48pgmc@yahoo.com">bvs48pgmc@yahoo.com</a> 09418470678; Fax: 07172566671 <a href="mailto:tgsaurav10@yahoo.com">tgsaurav10@yahoo.com</a> (094181-66601) 0717-2566671 <a href="mailto:surenderkashyap@hotmail.co">surenderkashyap@hotmail.co</a> 0177-2804251, 2808011, 2905502, 9419670678 Fax: 0177-2658339</td>
</tr>
<tr>
<td>National Institute of Mental Health &amp; Neuro Sciences, P.B. No.2900, Hapur Road, Bangalore 560029 (NIMHANS, Bangalore)</td>
<td><a href="mailto:dm@nimhans.krc.in">dm@nimhans.krc.in</a> 091-080-2699501/2654140, 2656181, 2656682 Fax: 091-080-2696140 <a href="mailto:clv@nimhans.krc.in">clv@nimhans.krc.in</a> (940333333) <a href="mailto:sureshsraavi@gmail.com">sureshsraavi@gmail.com</a> (8094565126) <a href="mailto:vmahesh_55@gmail.com">vmahesh_55@gmail.com</a> (9341771700) <a href="mailto:anshushivastav@gmail.com">anshushivastav@gmail.com</a> (9886809644)</td>
</tr>
<tr>
<td>JIPMER, Dhinavanti Nagar, Gorimedu, Pondicherry 600006</td>
<td>Subbarao <a href="mailto:lvsk@rediffmail.com">lvsk@rediffmail.com</a> 0413-2273067 Fax: 0413-2273066 <a href="mailto:sujatha.sistla@gmail.com">sujatha.sistla@gmail.com</a> (9894058062) <a href="mailto:Carolyne.basile@yahoo.com">Carolyne.basile@yahoo.com</a> (9940309807)</td>
</tr>
<tr>
<td>Haffkine’s Institute, Haffkirs Bio-Pharma Company Ltd., Achariya Dorde Marg, Parel, Mumbai-400012</td>
<td><a href="mailto:abhayachoudhary@yahoo.com">abhayachoudhary@yahoo.com</a> 9821090505 Fax: 022-24150826 <a href="mailto:pallamtla133@yahoo.com">pallamtla133@yahoo.com</a> (983062214) <a href="mailto:sandeepparma@gmail.com">sandeepparma@gmail.com</a> (9819064464)</td>
</tr>
<tr>
<td>CRI, Kasauli-273204</td>
<td><a href="mailto:drkumar@yahoo.com">drkumar@yahoo.com</a> <a href="mailto:sandeepchakravarty@yahoo.in">sandeepchakravarty@yahoo.in</a> 9891638145 01792-272059, 272060 Fax: 01792-272049, 272016 <a href="mailto:sandeepchakravarty@gmail.in">sandeepchakravarty@gmail.in</a> 09891638145 Fax: 01792-272016 <a href="mailto:san_156@rediffmail.com">san_156@rediffmail.com</a> (9816138860)</td>
</tr>
<tr>
<td>IPM PH Lab &amp; F (H) Administration, Narayanguda, Hyderabad-500029 (IPM, Hyderabad)</td>
<td><a href="mailto:dirnpi@yahoo.co.in">dirnpi@yahoo.co.in</a> Fax: 040-27567894 <a href="mailto:yogana.d@gmail.com">yogana.d@gmail.com</a> 040-27568167 949076377</td>
</tr>
<tr>
<td>B.J. Medical College, Asarwa, Ahmedabad-380016 (Gujarat) (BJMC, Ahmedabad)</td>
<td><a href="mailto:nidhiisood@yahoo.co.in">nidhiisood@yahoo.co.in</a> (9429060036) Fax : 079-22681470 9377436610 ; Fax : 079-22681470</td>
</tr>
<tr>
<td>Kasturba Medical College, Manipal University, Manipal, Karnataka (KMC, Manipal)</td>
<td><a href="mailto:srirath.nra@manipal.edu">srirath.nra@manipal.edu</a> 0820-2570062 <a href="mailto:anuruvio@gmail.com">anuruvio@gmail.com</a> 09845584163 Fax : 0820-2570062</td>
</tr>
<tr>
<td>National Centre for Disease Control, 22, Shahnath Marg, Delhi-54</td>
<td><a href="mailto:Shashi.Khare@hotmail.com">Shashi.Khare@hotmail.com</a>, <a href="mailto:aimircnc@gmail.com">aimircnc@gmail.com</a> Tel/fax: 011-23912506</td>
</tr>
</tbody>
</table>
CD Alert is a monthly newsletter of the National Centre for Disease Control (NCDC) (formerly known as NICD), Directorate General of Health Services, to disseminate information on various aspects of communicable diseases to medical fraternity and health administrators. The newsletter may be reproduced, in part or whole, for educational purposes.

Chief Editor: Dr. R. K. Srivastava

Editorial Board: Dr. Shiv Lal, Dr. R. L. Ichhapurani, Dr. Shashi Khare, Dr. A. K. Harit

Guest Editor (Authors): Dr. Archana Aravindan, Dr. Jagvir Singh, Dr Arli Bahl, Dr Shashi Khare

Publisher: Director, National Centre for Disease Control, 22 Shahnath Marg, Delhi 110 054

Tel: 011-23971272, 23971060 Fax: 011-23922677

E-mail: dirnicd@bol.net.in and dirnicd@gmail.com Website: www.nicd.nic.in

Acknowledgement: Financial assistance by WHO/USAID is duly acknowledged.